InsidersTradesSigma
Total declarations
Company
▲ Purchases (6 ops.)
▼ Sales (0 ops.)
Discover the complete record of transactions filed by ADAMS ERIC A, Chairman & CEO. Insider active across 1 companies, notably InMed Pharmaceuticals Inc.. Cumulatively, 6 disclosures have been recorded. Total volume traded: €79k. The latest transaction was filed on 14 April 2022 — Acquisition. Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations6 total
€11,69914,160 shares@ €0.82620.18% mcap14.8% of flow
Common Stock
SEC:0001213900-22-020314:0·
Ideal exit: 9 Jan 2023 (T+270)
€6,6778,560 shares@ €0.78010.10% mcap8.5% of flow
Common Stock
SEC:0001213900-22-019688:0·
Ideal exit: 8 Jan 2023 (T+270)
€13,1228,800 shares@ €1.491243.4% of flow
Common Stock
SEC:0001213900-21-050751·
Ideal exit: 26 Jun 2022 (T+270)
€13,1228,800 shares@ €1.49120.20% mcap16.6% of flow
Common Stock
SEC:0001213900-21-050751:0·
Ideal exit: 26 Jun 2022 (T+270)
€17,10011,400 shares@ €1.5056.6% of flow
Common Stock
SEC:0001213900-21-050522·
Ideal exit: 25 Jun 2022 (T+270)
€17,10011,400 shares@ €1.500.26% mcap21.7% of flow
Common Stock
SEC:0001213900-21-050522:0·
Ideal exit: 25 Jun 2022 (T+270)
6 of 6 declarations
About ADAMS ERIC A
Eric A. Adams is the President & CEO of InMed Pharmaceuticals Inc. He oversees the company's operations and is responsible for the overall strategy. With a strong background in the pharmaceutical sector, Eric A. Adams is committed to advancing InMed Pharmaceuticals Inc.'s initiatives to develop innovative treatments.
